Following the discontinuation of pociredir for sickle cell disease, Fulcrum Therapeutics implemented a restructuring plan to reduce expenses. On June 5 and June 11, 2026, the company approved cash retention payments for its nine remaining full-time employees, including $370,040 for CEO Alex C. Sapir, $195,480 for CLO Curtis Oltmans, and $195,200 for CFO Alan Musso, payable upon a Change in Control or termination without Cause. Additionally, the company announced that Greg Tourangeau, VP of Finance and principal accounting officer, will depart on a mutually agreed date, noting no disagreements over financial reporting. Fulcrum Therapeutics is a biotechnology company that develops therapies for rare diseases.